Thrilled to share a significant milestone: Our groundbreaking research paper on pretargeted radioimmunotherapy using the novel PreTarg-it® antibody ON105, titled “Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer,” is now published in the AACR Journal Molecular Cancer Therapeutics.
This paper explores the PreTarg-it® platform, a novel two-step regimen for optimized payload delivery in pretargeted radioimmunotherapy. Our study demonstrates the effectiveness of ON105, a bispecific antibody targeting oxMIF and the HSG hapten, combined with the radioactively labeled DOTA-di-HSG peptide in murine cancer models. Notably, this approach achieved 100% survival at the study endpoint. The findings highlight PreTarg-it®’s potential as a potent therapy for hard-to-treat solid tumors, including pancreatic cancer, and late-stage malignancies.
Congratulations to first authors Alejandro Puchol and Alexander Schinagl for their remarkable contributions. We are proud of our team’s dedication and extend special thanks to all collaborators for their invaluable contributions to this achievement.